EMA / Covid19: Longer-term vaccine approval procedures safer
What did Coreper say about the approval of the vaccine in Britain
The European Union's Drugs Regulatory Authority said today that its longer procedures for approving vaccines against Covid-19 are safer, after the UK approves urgent procedures of the experimental vaccine developed by Pfizer and BioNTech.
Asked about the UK approval for the Pfizer vaccine, the European Medicines Agency (EMA) said: "The EMA considers the conditional marketing authorization to be the most appropriate regulatory mechanism to be used in the current emergency need due to pandemic ". The EMA added that this procedure is based on more data and more controls than the urgent procedure chosen by Britain.
The EMA announced yesterday, Tuesday, that it will decide by December 29, whether to approve the Pfizer vaccine.